Sato Vicki L's Form 4 filing
Denali Therapeutics Inc. (DNLI) · filed Jul 3, 2024
- Accession no.
- 0001714899-24-000155
- Filed
- Jul 3, 2024
- Trade date
- Jul 1, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $68.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sato Vicki LCIK 0001197020 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 1, 2024 | Common Stock | SSaleDisposed | −2,980 | $22.12 | −$65,917.6 | 119,356 | Direct | |
| Jul 1, 2024 | Common Stock | SSaleDisposed | −100 | $22.86 | −$2,286 | 119,256 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.